TCGA-CR-7401-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
- NOTCH_SIGNALING+0.510
- ANGIOGENESIS+0.420
- APICAL_JUNCTION+0.360
- HEDGEHOG_SIGNALING+0.330
- PANCREAS_BETA_CELLS+0.300
- PROTEIN_SECRETION+0.300
- UV_RESPONSE_DN+0.290
- ESTROGEN_RESPONSE_EARLY+0.270
Top 10 suppressed
- E2F_TARGETS-0.540
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V2-0.470
- MYC_TARGETS_V1-0.380
- MITOTIC_SPINDLE-0.290
- DNA_REPAIR-0.260
- SPERMATOGENESIS-0.230
- TNFA_SIGNALING_VIA_NFKB-0.190
- UV_RESPONSE_UP-0.120
- UNFOLDED_PROTEIN_RESPONSE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d1ecfbcd-8e13-4c5c-8536-6fb1e878e193 | — | — | 0.854 |
| 2 | SRR8518203 | — | A | 0.837 |
| 3 | TCGA-CR-7386-01A-11R-2016-07 | — | — | 0.835 |
| 4 | TCGA-BH-A0AZ-01A-21R-A12P-07 | — | A | 0.834 |
| 5 | TCGA-38-4627-01A-01R-1206-07 | — | cohortA1 | 0.831 |
| 6 | TCGA-CV-7411-01A-11R-2081-07 | — | — | 0.826 |
| 7 | SRR27320696 | — | — | 0.821 |
| 8 | BS_470DYRJQ | pilocytic astrocytoma | — | 0.819 |
| 9 | C3L-02552 | — | cohortSQ1 | 0.818 |
| 10 | 80ff3d8c-da3f-4a1f-822c-c6132e2b0574 | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.580 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.510 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.360 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |